Teva Pharmaceutical Industries (TEVA) Non-Current Deferred Tax Liability (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Non-Current Deferred Tax Liability for 18 consecutive years, with $273.0 million the latest figure, recorded in Q1 2026.

• Quarterly Non-Current Deferred Tax Liability fell 40.78% year-over-year to $273.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $273.0 million (down 40.78% YoY) and the FY2025 annual result came in at $296.0 million, down 38.72% from the prior year.
• Non-Current Deferred Tax Liability fell to $273.0 million in Q1 2026 per TEVA's latest filing, from $296.0 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for TEVA reached as high as $666.0 million in Q1 2022 and fell as low as $273.0 million in Q1 2026.
• A 5-year average of $499.7 million and a median of $534.0 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability tumbled 44.73% — and 2023, when it gained 10.58%.
• Year by year, Non-Current Deferred Tax Liability stood at $548.0 million in 2022, then gained by 10.58% to $606.0 million in 2023, then dropped by 20.3% to $483.0 million in 2024, then slumped by 38.72% to $296.0 million in 2025, then fell by 7.77% to $273.0 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $273.0 million, $296.0 million, and $399.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.